- MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
- MiNK Reports Fourth Quarter and Year-End 2023 Results
- MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
- MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
- First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
- MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
- MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
- ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
- MiNK Therapeutics Reports Third Quarter 2023 Results
- MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
More ▼
Key statistics
As of last trade, Mink Therapeutics Inc (INKT:NAQ) traded at 0.8985, 19.80% above the 52 week low of 0.75 set on Jan 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8705 |
---|---|
High | 0.90 |
Low | 0.861 |
Bid | 0.88 |
Offer | 0.8999 |
Previous close | 0.8717 |
Average volume | 135.11k |
---|---|
Shares outstanding | 34.70m |
Free float | 9.94m |
P/E (TTM) | -- |
Market cap | 30.25m USD |
EPS (TTM) | -0.6538 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 18:45 BST.
More ▼